PRL-02 injection + prednisone + dexamethasone + enzalutamide
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Trial Timeline
Jun 14, 2021 → May 31, 2029
NCT ID
NCT04729114About PRL-02 injection + prednisone + dexamethasone + enzalutamide
PRL-02 injection + prednisone + dexamethasone + enzalutamide is a phase 1 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04729114. Target conditions include Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04729114 | Phase 1 | Recruiting |
Competing Products
20 competing products in Prostate Cancer